Boothbay Fund Management, LLC Black Diamond Therapeutics, Inc. Transaction History

Boothbay Fund Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.77 - $3.03 $38,205 - $65,402	21,585 Added 18.02%	141,347 $397,000
Q3 2023 Nov 14, 2023	BUY	$2.87 - $4.99 $30,046 - $52,240	10,469 Added 9.58%	119,762 $343,000
Q2 2023 Aug 14, 2023	BUY	$1.43 - $6.18 $156,288 - $675,430	109,293 New	109,293 $551,000
Q2 2022 Aug 15, 2022	SELL	$1.5 - $3.63 $22,396 - $54,199	-14,931 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$8.46 - $12.42 $53,746 - $78,904	-6,353 Reduced 29.85%	14,931 $126,000
Q2 2021 Aug 16, 2021	BUY	$12.19 - $28.17 $22,368 - $51,691	1,835 Added 9.43%	21,284 $259,000
Q1 2021 May 17, 2021	SELL	$22.23 - $34.75 $384,845 - $601,592	-17,312 Reduced 47.09%	19,449 $472,000
Q4 2020 Feb 12, 2021	SELL	$29.47 - $35.0 $180,150 - $213,955	-6,113 Reduced 14.26%	36,761 $1.18 Million
Q3 2020 Nov 16, 2020	BUY	$26.17 - $43.07 $545,539 - $897,837	20,846 Added 94.63%	42,874 $1.3 Million
Q2 2020 Aug 14, 2020	BUY	$22.3 - $44.8 $491,224 - $986,854	22,028 New	22,028 $929,000

47.6M

2.9K

69.4K

Ticker BDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,339,500
Market Cap $78.5M
Description
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.